Patent · US Active

Modified binding polypeptides for optimized drug conjugation

US11879004B2 · kind B2 · utility

0Cited by

30References

26Claims

0Family size

Assignee

Genzyme Corporation · US

Inventors

Qun Zhou · Ashland, US
Sunghae Park · Bound Brook, US
Huawei Qiu · Westborough, US
Marie-Priscille BRUN · Paris, FR
Francis Duffieux · Paris, FR

Key dates

Filing date	Feb 26, 2021
Grant date	Jan 23, 2024
Priority date	—
Expiry date	Jun 18, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Engineered antibodies that are stable and can be conjugated to a ligand or drug at a ligand/drug to antibody ratio of above 3, making these conjugates suitable for treatment of a variety of indications, are provided. Methods of producing these engineered antibodies are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.